Johnson & Johnson stock (US4781601046): Q1 2026 beat underpins steady valuation focus

Johnson & Johnson shares on the NYSE were little changed on Friday as investors digested the company’s stronger-than-expected Q1 2026 results and looked ahead to the scheduled Q2 earnings call in July, keeping the focus on valuation metrics after a solid year-to-date performance.

Johnson & Johnson shares traded around the mid-USD 240s on the New York Stock Exchange on 05/29/2026, leaving the stock roughly flat on the day as investors continued to weigh a robust first-quarter 2026 earnings beat against an already solid year-to-date performance for one of the largest healthcare names in the United States.

According to price data from Business Insider as of 05/29/2026, the stock’s 52-week high stands at USD 251.60, putting the current price modestly below recent peaks and highlighting that the United States-listed blue chip remains within sight of its record territory.

From a broader performance perspective, a Zacks commentary on 05/28/2026 noted that Johnson & Johnson shares have gained about 11.8% year to date, materially outperforming many large-cap healthcare peers over the same period as markets reward the company’s steady earnings profile and diversified revenue base.

The same analysis highlighted that over the past 12 months the stock price has risen roughly 50.6%, compared with a gain of 26.1% for its broader industry group, underscoring how the New Brunswick, New Jersey-based healthcare group has benefited from investor appetite for resilient cash-flow generators.

On the fundamental side, the key driver of sentiment in recent weeks has been the first-quarter 2026 report, where Johnson & Johnson delivered revenue of about USD 24.1 billion, up 6.4% year on year, compared with analyst expectations of roughly USD 23.61 billion, and posted adjusted earnings per share of USD 2.70 versus consensus of about USD 2.68, according to figures summarized by Investing.com from the company’s disclosures on 04/16/2026.

Those numbers meant that Johnson & Johnson beat Wall Street estimates on both the top and bottom line for Q1 2026, supporting the stock’s constructive trajectory even as some investors monitor product-specific dynamics such as pressure on Stelara sales and the evolving mix between its Innovative Medicine and MedTech franchises.

Looking ahead, the company announced on 05/27/2026 that it will host an investor conference call to discuss second-quarter 2026 results, giving United States investors a clear date marker for the next major information catalyst from management after the Q1 beat.

For investors following the stock in Germany, Johnson & Johnson also trades on off-exchange venues such as Tradegate in euros, providing an additional access point alongside its primary New York Stock Exchange listing in US dollars.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Johnson & Johnson
• Sector/industry: Healthcare, pharmaceuticals and medical technology
• Headquarters/country: New Brunswick, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Innovative Medicine pharmaceuticals and MedTech devices
• Home exchange/listing venue: New York Stock Exchange (JNJ)
• Trading currency: USD

Johnson & Johnson: core business model

Johnson & Johnson generates revenue primarily by developing, manufacturing and marketing prescription medicines and medical devices across its Innovative Medicine and MedTech segments, with growth depending on product launches, patent cycles and procedure volumes in its key global healthcare markets.

Valuation metrics and multiples for Johnson & Johnson

After the Q1 2026 results release on 04/16/2026, analyst commentary compiled by Zacks on 05/28/2026 indicated that earnings expectations have inched higher, with the consensus estimate for 2026 earnings per share rising from USD 11.54 to USD 11.57 over the past 60 days and the 2027 EPS estimate moving from USD 12.44 to USD 12.58 in the same period, suggesting that the market now embeds a slightly stronger medium-term profit trajectory into its valuation framework.

Although exact real-time valuation ratios vary with intraday price moves, the combination of an 11.8% year-to-date share price gain, consistent earnings growth, and rising forward EPS estimates has led many investors to evaluate Johnson & Johnson’s price-to-earnings and enterprise-value-based multiples relative to its historical range and to other large-cap healthcare names, rather than focusing solely on near-term price fluctuations.

Conclusion

Johnson & Johnson’s share price on the New York Stock Exchange held close to recent levels on 05/29/2026 as the market continued to absorb the impact of a Q1 2026 earnings beat and anticipate the upcoming Q2 earnings call later this year.

With the stock up about 11.8% year to date and analyst EPS forecasts for 2026 and 2027 edging higher in recent weeks, valuation metrics remain a central focus for investors comparing this diversified healthcare leader to other large-cap names in the sector.

How the company balances product-level headwinds, new launches and capital allocation in the coming quarters will likely determine whether current multiples are sustained, expand further, or normalize closer to long-run averages.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.